Rothbard R L, Anderson J L, Fitzpatrick P G, Hakworthy R A, Sorensen S G, Marder V J
University of Rochester School of Medicine, New York.
Clin Cardiol. 1990 Mar;Suppl 5:V11-4; discussion V27-32. doi: 10.1002/clc.4960131304.
Adverse events data of a randomized, multicenter, angiographically controlled trial of intracoronary streptokinase and intravenous anistreplase, or anisoylated plasminogen streptokinase activator complex (APSAC) are presented. The frequency of severe adverse events is similar for streptokinase and anistreplase; no unexpected adverse experiences were reported with either drug. The most frequently encountered side effect was bleeding, overwhelmingly from the groin puncture site from angiography.
本文呈现了一项关于冠状动脉内链激酶与静脉注射茴香酰化纤溶酶原链激酶激活剂复合物（APSAC），即茴香酰化纤溶酶原-链激酶激活剂复合物，的随机、多中心、血管造影对照试验的不良事件数据。链激酶和茴香酰化纤溶酶原链激酶激活剂复合物严重不良事件的发生频率相似；两种药物均未报告意外不良事件。最常出现的副作用是出血，绝大多数出血来自血管造影时的腹股沟穿刺部位。
